In this study, we aimed to contextualize how PSMA-PET may influence the interpretation of the EMBARK trial results.5 In this retrospective study of 182 patients with nmHSPC eligible for the EMBARK trial (based on conventional imaging), we demonstrated that PSMA-PET detected metastatic disease in 46% of all patients, suggesting that a significant number of patients have disease that is understaged by conventional imaging. This evidence concerns the gene FOLH1 and metastatic neoplasm.